HK1121459A1 - Aspartic protease inhibitors - Google Patents
Aspartic protease inhibitorsInfo
- Publication number
- HK1121459A1 HK1121459A1 HK09101679.7A HK09101679A HK1121459A1 HK 1121459 A1 HK1121459 A1 HK 1121459A1 HK 09101679 A HK09101679 A HK 09101679A HK 1121459 A1 HK1121459 A1 HK 1121459A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- protease inhibitors
- aspartic protease
- aspartic
- inhibitors
- protease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73656405P | 2005-11-14 | 2005-11-14 | |
US84533106P | 2006-09-18 | 2006-09-18 | |
US84529106P | 2006-09-18 | 2006-09-18 | |
PCT/US2006/043920 WO2007070201A1 (en) | 2005-11-14 | 2006-11-13 | Aspartic protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1121459A1 true HK1121459A1 (en) | 2009-04-24 |
Family
ID=37812974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09101679.7A HK1121459A1 (en) | 2005-11-14 | 2009-02-23 | Aspartic protease inhibitors |
Country Status (16)
Country | Link |
---|---|
US (1) | US8487108B2 (xx) |
EP (1) | EP1966139B1 (xx) |
JP (1) | JP2009515893A (xx) |
KR (1) | KR101379663B1 (xx) |
AR (1) | AR057890A1 (xx) |
AT (1) | ATE538092T1 (xx) |
AU (1) | AU2006325322B2 (xx) |
BR (1) | BRPI0618585A2 (xx) |
CA (1) | CA2628952C (xx) |
HK (1) | HK1121459A1 (xx) |
NO (1) | NO20082108L (xx) |
NZ (1) | NZ568042A (xx) |
PE (2) | PE20070804A1 (xx) |
SG (1) | SG169983A1 (xx) |
TW (1) | TWI411607B (xx) |
WO (1) | WO2007070201A1 (xx) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754737B2 (en) | 2004-10-07 | 2010-07-13 | Vitae Pharmaceuticals, Inc. | Diaminoalkane aspartic protease inhibitors |
WO2007117560A2 (en) * | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Piperidine and morpholine renin inhibitors |
WO2007117482A2 (en) * | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
US20090264428A1 (en) * | 2006-04-05 | 2009-10-22 | Baldwin John J | Renin Inhibitors |
US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
JP2010503682A (ja) * | 2006-09-18 | 2010-02-04 | ビテ ファーマシューティカルズ, インコーポレイテッド | レニン阻害剤としてのピペリジン誘導体 |
WO2009038715A1 (en) * | 2007-09-17 | 2009-03-26 | Vitae Pharmaceuticals, Inc. | Process for the preparation of renin inhibitors |
WO2009038719A1 (en) * | 2007-09-17 | 2009-03-26 | Vitae Pharmaceuticals, Inc. | Process for the preparation of renin inhibitors |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
US20100010228A1 (en) * | 2008-06-26 | 2010-01-14 | Vitae Pharmaceuticals, Inc. | Process for the asymmetric reduction of 3-benzoylpiperidines |
EP2306826A4 (en) * | 2008-06-26 | 2011-07-27 | Vitae Pharmaceuticals Inc | SALTS OF METHYL-2 - ((R)) - (3-CHLOROPHENYL) ((R) 1 - ((S) -2- (METHYLAMINO) -3 ((R) -TETRAHYDRO-2H-PYRAN-3-YL) propylcarbamoyl) piperidin-3-yl) methoxy) ETHYL CARBAMATE |
MY153606A (en) | 2008-08-05 | 2015-02-27 | Daiichi Sankyo Co Ltd | Imidazopyridin-2-one derivatives |
WO2010111634A2 (en) * | 2009-03-26 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
US20110021570A1 (en) | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
WO2012081582A1 (ja) * | 2010-12-15 | 2012-06-21 | 国立大学法人北海道大学 | ジアステレオ選択的にアルコール化合物を製造する方法及びルテニウム化合物 |
JP5616977B2 (ja) * | 2010-12-15 | 2014-10-29 | 国立大学法人北海道大学 | 光学活性アルコール化合物の製造方法 |
WO2014028800A1 (en) | 2012-08-16 | 2014-02-20 | Janssen Pharmaceutica Nv | Substituted pyrazoles as n-type calcium channel blockers |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
WO2023217989A1 (en) | 2022-05-12 | 2023-11-16 | Syngenta Crop Protection Ag | Alkoxy heteroaryl- carboxamide or thioamide compounds |
WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3071618A (en) | 1956-02-02 | 1963-01-01 | Pfizer & Co C | Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines |
GB1351761A (en) | 1971-02-04 | 1974-05-01 | Wilkinson Sword Ltd | Substituted p-menthane carboxamides and compositions containing them |
US4136163A (en) | 1971-02-04 | 1979-01-23 | Wilkinson Sword Limited | P-menthane carboxamides having a physiological cooling effect |
JPS5115098A (ja) | 1974-07-26 | 1976-02-06 | Asahi Chemical Ind | Akurirukeiseniseihinno shorihoho |
US4594343A (en) * | 1984-10-19 | 1986-06-10 | Shanklin Jr James R | 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles |
GB8810067D0 (en) | 1988-04-28 | 1988-06-02 | Ucb Sa | Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides |
US4908372A (en) | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
US5552558A (en) | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
DE4018070A1 (de) | 1990-06-06 | 1991-12-12 | Bayer Ag | Morpholinoharnstoff-derivate |
HUT64320A (en) | 1990-12-14 | 1993-12-28 | Merrell Dow Pharma | Process for production antiallergic imidazole derivatives and pharmaceutical preparations containing these compounds |
ES2163407T3 (es) | 1992-02-13 | 2002-02-01 | Merrell Pharma Inc | Derivados piperidinilos tiaciclicos. |
ES2143058T3 (es) | 1994-07-29 | 2000-05-01 | Abbott Lab | Procedimiento de preparacion de un 2,5-diamino-3-hidroxihexano sustituido. |
US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
WO1998054179A1 (en) | 1997-05-29 | 1998-12-03 | Eli Lilly And Company | Process for preparing heterocyclic compounds |
WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
GB9826540D0 (en) | 1998-12-02 | 1999-01-27 | Darwin Discovery Ltd | Process |
AU2492500A (en) * | 1999-01-06 | 2000-07-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aspartic protease inhibitors, compositions, and associated therapeutic methods |
JP2000302757A (ja) | 1999-04-16 | 2000-10-31 | Shiseido Co Ltd | N−置換ピペリジン誘導体 |
US7071184B2 (en) | 2000-03-21 | 2006-07-04 | Smithkline Beecham Corporation | Protease inhibitors |
US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
AU2002320490B2 (en) | 2001-07-11 | 2008-10-02 | Elan Pharmaceuticals, Inc. | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
IL161881A0 (en) * | 2001-11-08 | 2005-11-20 | Upjohn Co | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
UA80819C2 (en) | 2002-04-26 | 2007-11-12 | Gilead Sciences Inc | Phosphonate analogs of compounds inhibiting hiv proteases, pharmaceutical composition on their basis and their use |
WO2004002483A1 (en) * | 2002-06-27 | 2004-01-08 | Actelion Pharmaceuticals Ltd | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease |
US7557137B2 (en) | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
JP2005538177A (ja) | 2002-09-10 | 2005-12-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | アルツハイマー病処置用置換アミノエーテル化合物 |
WO2005049027A2 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US20070093492A1 (en) | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
US20060063930A1 (en) | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
US7754737B2 (en) * | 2004-10-07 | 2010-07-13 | Vitae Pharmaceuticals, Inc. | Diaminoalkane aspartic protease inhibitors |
PL1882684T3 (pl) | 2005-05-19 | 2015-08-31 | Astellas Pharma Inc | Pochodna pirolidyny albo jej sól |
US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
WO2007117560A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Piperidine and morpholine renin inhibitors |
JP2010503682A (ja) | 2006-09-18 | 2010-02-04 | ビテ ファーマシューティカルズ, インコーポレイテッド | レニン阻害剤としてのピペリジン誘導体 |
CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
EP2167609A1 (en) | 2007-06-20 | 2010-03-31 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
US20100160424A1 (en) | 2007-06-20 | 2010-06-24 | Baldwin John J | Renin inhibitors |
US7773441B2 (en) * | 2008-06-18 | 2010-08-10 | Micron Technology, Inc. | Memory malfunction prediction system and method |
JP2011525488A (ja) | 2008-06-20 | 2011-09-22 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | レニン阻害剤およびその使用方法 |
EP2306826A4 (en) | 2008-06-26 | 2011-07-27 | Vitae Pharmaceuticals Inc | SALTS OF METHYL-2 - ((R)) - (3-CHLOROPHENYL) ((R) 1 - ((S) -2- (METHYLAMINO) -3 ((R) -TETRAHYDRO-2H-PYRAN-3-YL) propylcarbamoyl) piperidin-3-yl) methoxy) ETHYL CARBAMATE |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
-
2006
- 2006-10-31 TW TW095140163A patent/TWI411607B/zh not_active IP Right Cessation
- 2006-11-13 AT AT06837406T patent/ATE538092T1/de active
- 2006-11-13 CA CA2628952A patent/CA2628952C/en not_active Expired - Fee Related
- 2006-11-13 NZ NZ568042A patent/NZ568042A/en not_active IP Right Cessation
- 2006-11-13 PE PE2006001432A patent/PE20070804A1/es not_active Application Discontinuation
- 2006-11-13 EP EP06837406A patent/EP1966139B1/en active Active
- 2006-11-13 AU AU2006325322A patent/AU2006325322B2/en not_active Ceased
- 2006-11-13 WO PCT/US2006/043920 patent/WO2007070201A1/en active Application Filing
- 2006-11-13 KR KR1020087014407A patent/KR101379663B1/ko not_active IP Right Cessation
- 2006-11-13 US US12/084,928 patent/US8487108B2/en not_active Expired - Fee Related
- 2006-11-13 JP JP2008540236A patent/JP2009515893A/ja not_active Withdrawn
- 2006-11-13 BR BRPI0618585-1A patent/BRPI0618585A2/pt not_active IP Right Cessation
- 2006-11-13 SG SG201101062-6A patent/SG169983A1/en unknown
- 2006-11-14 AR ARP060104967A patent/AR057890A1/es unknown
-
2008
- 2008-05-07 NO NO20082108A patent/NO20082108L/no not_active Application Discontinuation
-
2009
- 2009-02-23 HK HK09101679.7A patent/HK1121459A1/xx not_active IP Right Cessation
-
2010
- 2010-08-06 PE PE2010000496A patent/PE20120229A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20080069685A (ko) | 2008-07-28 |
PE20120229A1 (es) | 2012-04-04 |
US8487108B2 (en) | 2013-07-16 |
PE20070804A1 (es) | 2007-09-06 |
KR101379663B1 (ko) | 2014-04-14 |
JP2009515893A (ja) | 2009-04-16 |
TWI411607B (zh) | 2013-10-11 |
ATE538092T1 (de) | 2012-01-15 |
AR057890A1 (es) | 2007-12-26 |
NO20082108L (no) | 2008-08-06 |
SG169983A1 (en) | 2011-04-29 |
EP1966139B1 (en) | 2011-12-21 |
TW200800893A (en) | 2008-01-01 |
WO2007070201A1 (en) | 2007-06-21 |
BRPI0618585A2 (pt) | 2011-09-27 |
AU2006325322A1 (en) | 2007-06-21 |
NZ568042A (en) | 2010-12-24 |
AU2006325322B2 (en) | 2011-08-04 |
CA2628952C (en) | 2014-04-01 |
CA2628952A1 (en) | 2007-06-21 |
US20100048636A1 (en) | 2010-02-25 |
EP1966139A1 (en) | 2008-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1121459A1 (en) | Aspartic protease inhibitors | |
ZA200710386B (en) | Aspartyl protease inhibitors | |
IL187814A0 (en) | Aspartyl protease inhibitors | |
ZA200710337B (en) | Aspartyl protease inhibitors | |
IL182305A0 (en) | Diaminoalkane aspartic protease inhibitors | |
PT1981519T (pt) | Inibição de protéases | |
HK1096956A1 (en) | Cysteine protease inhibitors | |
HK1119680A1 (en) | Heterocyclic aspartyl protease inhibitors | |
IL192134A0 (en) | Soft protease inhibitors and pro-soft forms thereof | |
EP1906945A4 (en) | HCV INHIBITORS | |
ATE530554T1 (de) | Serinprotease-hemmer | |
EP1750696B1 (en) | RETROVIRAL PROTEASE INHIBITORS RESISTING THEIR RESISTANCE | |
EP1732891A4 (en) | RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES | |
EP1839669A4 (en) | NEW ANGIOGENESEHEMMER | |
GB0513841D0 (en) | Cysteine protease inhibitors | |
IL177055A0 (en) | Silinae compounds as cysteine protease inhibitors | |
IL183850A0 (en) | Hiv protease inhibitors | |
EP2064177A4 (en) | PROTEASE INHIBITORS | |
EP1855672A4 (en) | HIV PROTEASE INHIBITORS | |
GB0513839D0 (en) | Cysteine protease inhibitors | |
GB0513840D0 (en) | Cysteine protease inhibitors | |
ZA200804025B (en) | Aspartic protease inhibitors | |
ZA200706305B (en) | HIV protease inhibitors | |
GB0516967D0 (en) | Inhibitors | |
GB0507628D0 (en) | Protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20151113 |